# OnCo record paper-atezolizumab-hcc-j-hepatol-2022 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-atezolizumab-hcc-j-hepatol-2022/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-atezolizumab-hcc-j-hepatol-2022" ;
  schema:name "Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma"@en ;
  schema:description "Phase 2 or 3 results paper on Atezolizumab in Hepatocellular carcinoma, in Journal of hepatology (2022), one of the most cited Europe PMC records with Atezolizumab in its title."@en ;
  schema:url <https://onco.cc/key-papers/paper-atezolizumab-hcc-j-hepatol-2022/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/j.jhep.2021.11.030>, <https://pubmed.ncbi.nlm.nih.gov/34902530/>, <https://europepmc.org/article/MED/34902530>, <https://clinicaltrials.gov/study/NCT03434379> ;
  onco:tag "europepmc-ingest" ;
  schema:sameAs <https://doi.org/10.1016/j.jhep.2021.11.030> ;
  schema:datePublished "2022"^^xsd:gYear ;
  schema:author "Cheng AL, Qin S, Ikeda M, et al." ;
  onco:trials <https://onco.cc/trials/imbrave150/> .